A feasibility trial of gamma sensory flicker for patients with prodromal Alzheimer's disease

被引:66
|
作者
He, Qiliang [1 ,2 ]
Colon-Motas, Kay M. [3 ]
Pybus, Alyssa F. [1 ,2 ,4 ,5 ]
Piendel, Lydia [3 ]
Seppa, Jonna K. [3 ]
Walker, Margaret L. [3 ,6 ]
Manzanares, Cecelia M. [3 ,6 ]
Qiu, Deqiang [1 ,2 ,6 ,7 ]
Miocinovic, Svjetlana [1 ,2 ,3 ,6 ]
Wood, Levi B. [1 ,2 ,4 ,5 ]
Levey, Allan I. [3 ,6 ]
Lah, James J. [3 ,6 ]
Singer, Annabelle C. [1 ,2 ]
机构
[1] Georgia Inst Technol, Wallace H Coulter Dept Biomed Engn, 313 Ferst Dr,UAWSuite 3105, Atlanta, GA 30332 USA
[2] Emory Univ, Atlanta, GA 30332 USA
[3] Emory Univ, Emory Brain Hlth Ctr, Dept Neurol, Atlanta, GA USA
[4] Georgia Inst Technol, Parker H Petit Inst Bioengn & Biosci, Atlanta, GA USA
[5] Georgia Inst Technol, George W Woodruff Sch Mech Engn, Atlanta, GA USA
[6] Emory Univ, Goizueta Alzheimer Dis Res Ctr, Atlanta, GA USA
[7] Emory Univ, Dept Radiol & Imaging Sci, Sch Med, Atlanta, GA USA
关键词
amyloid beta; cytokines; default mode network; electrophysiology; feasibility trial; gamma stimulation; neural stimulation; prodromal Alzheimer's disease; sensory stimulation; PHASE-I TRIAL; STEM-CELLS; BRAIN; STIMULATION; MICROGLIA;
D O I
10.1002/trc2.12178
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Introduction We and collaborators discovered that flickering lights and sound at gamma frequency (40 Hz) reduce Alzheimer's disease (AD) pathology and alter immune cells and signaling in mice. To determine the feasibility of this intervention in humans we tested the safety, tolerability, and daily adherence to extended audiovisual gamma flicker stimulation. Methods Ten patients with mild cognitive impairment due to underlying AD received 1-hour daily gamma flicker using audiovisual stimulation for 4 or 8 weeks at home with a delayed start design. Results Gamma flicker was safe, tolerable, and adherable. Participants' neural activity entrained to stimulation. Magnetic resonance imaging and cerebral spinal fluid proteomics show preliminary evidence that prolonged flicker affects neural networks and immune factors in the nervous system. Discussion These findings show that prolonged gamma sensory flicker is safe, tolerable, and feasible with preliminary indications of immune and network effects, supporting further study of gamma stimulation in AD.
引用
收藏
页数:11
相关论文
共 50 条
  • [1] A phase III randomized trial of gantenerumab in prodromal Alzheimer's disease
    Ostrowitzki, Susanne
    Lasser, Robert A.
    Dorflinger, Ernest
    Scheltens, Philip
    Barkhof, Frederik
    Nikolcheva, Tania
    Ashford, Elizabeth
    Retout, Sylvie
    Hofmann, Carsten
    Delmar, Paul
    Klein, Gregory
    Andjelkovic, Mirjana
    Dubois, Bruno
    Boada, Merce
    Blennow, Kaj
    Santarelli, Luca
    Fontoura, Paulo
    ALZHEIMERS RESEARCH & THERAPY, 2017, 9
  • [2] Genistein, A Phytoestrogen, Delays the Transition to Dementia in Prodromal Alzheimer's Disease Patients
    Vina, Jose
    Borras, Consuelo
    Mas-Bargues, Cristina
    JOURNAL OF ALZHEIMERS DISEASE, 2024, 101 : S275 - S283
  • [3] Multimodal Magnetic Resonance Imaging in Alzheimer's Disease Patients at Prodromal Stage
    Eustache, Pierre
    Nemmi, Federico
    Saint-Aubert, Laure
    Pariente, Jeremie
    Peran, Patrice
    JOURNAL OF ALZHEIMERS DISEASE, 2016, 50 (04) : 1035 - 1050
  • [4] Recognition Memory Performance as a Cognitive Marker of Prodromal Alzheimer's Disease
    Goldstein, Felicia C.
    Loring, David W.
    Thomas, Tiffany
    Saleh, Sabria
    Hajjar, Ihab
    JOURNAL OF ALZHEIMERS DISEASE, 2019, 72 (02) : 507 - 514
  • [5] Economic evaluation of supplementing the diet with Souvenaid in patients with prodromal Alzheimer’s disease
    Javier Mar
    Ania Gorostiza
    Oliver Ibarrondo
    Igor Larrañaga
    Arantzazu Arrospide
    Pablo Martinez-Lage
    Myriam Soto-Gordoa
    Alzheimer's Research & Therapy, 12
  • [6] Profiling of Specific Gene Expression Pathways in Peripheral Cells from Prodromal Alzheimer's Disease Patients
    Serpente, Maria
    Fenoglio, Chiara
    Cioffi, Sara Maria Giulia
    Oldoni, Emanuela
    Arcaro, Marina
    Arighi, Andrea
    Fumagalli, Giorgio Giulio
    Ghezzi, Laura
    Scarpini, Elio
    Galimberti, Daniela
    JOURNAL OF ALZHEIMERS DISEASE, 2018, 61 (04) : 1289 - 1294
  • [7] Predictors of cognitive decline and treatment response in a clinical trial on suspected prodromal Alzheimer's disease
    Teipel, Stefan J.
    Cavedo, Enrica
    Grothe, Michel J.
    Lista, Simone
    Galluzzi, Samantha
    Colliot, Olivier
    Chupin, Marie
    Bakardjian, Hovagim
    Dormont, Didier
    Dubois, Bruno
    Hampel, Harald
    NEUROPHARMACOLOGY, 2016, 108 : 128 - 135
  • [8] Reduced basal forebrain atrophy progression in a randomized Donepezil trial in prodromal Alzheimer's disease
    Cavedo, Enrica
    Grothe, Michel J.
    Colliot, Olivier
    Lista, Simone
    Chupin, Marie
    Dormont, Didier
    Houot, Marion
    Lehericy, Stephane
    Teipel, Stefan
    Dubois, Bruno
    Hampel, Harald
    SCIENTIFIC REPORTS, 2017, 7
  • [9] Budget impact analysis of the use of Souvenaid in patients with prodromal Alzheimer’s Disease in Spain
    Javier Mar
    Oliver Ibarrondo
    Igor Larrañaga
    Lorea Mar-Barrutia
    Myriam Soto-Gordoa
    Alzheimer's Research & Therapy, 14
  • [10] Budget impact analysis of the use of Souvenaid in patients with prodromal Alzheimer's Disease in Spain
    Mar, Javier
    Ibarrondo, Oliver
    Larranaga, Igor
    Mar-Barrutia, Lorea
    Soto-Gordoa, Myriam
    ALZHEIMERS RESEARCH & THERAPY, 2022, 14 (01)